



Original Article

Protective Effect of Korean Red Ginseng on Cisplatin Ototoxicity: Is It Effective Enough?

Yüksel Olgun, Günay Kırkım, Zekiye Altun, Safiye Aktaş, Efsun Kolatan, Müge Kiray, Alper Bağrıyanık, Aybüke Olgun, Deniz Çakır Kızmazoğlu, Candan Özoğlu, Hülya Ellidokuz, Pınar Erçetin, Bülent Şerbetçioğlu, Osman Yılmaz, Enis Alpin Güneri

Department of Otorhinolaryngology, Dokuz Eylül University School Of Medicine, İzmir, Turkey (YO, GK, BŞ, EAG)

Department of Basic Oncology, Dokuz Eylül University School Of Medicine, İzmir, Turkey (ZA, SA, PE)

Department of Laboratory of Animal Science, Dokuz Eylül University School Of Medicine, İzmir, Turkey (EK)

Department of Physiology, Dokuz Eylül University School Of Medicine, İzmir, Turkey (MK)

Department of Histology, Dokuz Eylül University School Of Medicine, İzmir, Turkey (AB)

Department of Hematology, Dokuz Eylül University School Of Medicine, İzmir, Turkey (AO)

Department of Pediatric Oncology, Dokuz Eylül University School Of Medicine, İzmir, Turkey (DÇK)

Department of Histology, Gazi University School Of Medicine, İzmir, Turkey (CÖ)

Department of Biostatistics, Dokuz Eylül University School Of Medicine, İzmir, Turkey (HE)

OBJECTIVE: The aim of our study was to investigate the effects Korean Red Ginseng (KRG) on cisplatin (CDDP) ototoxicity in vivo and in vitro.

MATERIALS and METHODS: The first part of the study was conducted on the House Ear Institute-Organ of Corti 1 (HEI-OC1) cell line. Cells were treated with CDDP, KRG, and their combination for 24 h. Cell viability, apoptosis, and the expression of 84 apoptosis-related genes were analyzed. In the second part of the study, 30 Wistar albino rats were divided into five groups. Baseline distortion product otoacoustic emissions (DPOAEs) and auditory brainstem response (ABR) measurements were obtained. In groups I, II, and III, only saline, KRG, and CDDP, respectively, were given. In group IV, 500 mg/kg KRG and in group V, 150 mg/kg of KRG were administered for 10 days. In groups III, IV, and V, 16 mg/kg CDDP injections were administered on day 11. On day 14, final DPOAEs and ABR measurements were completed. The rats were then sacrificed, and their inner ear structures were evaluated by transmission electron microscopy.

RESULTS: In the first part of the study, pretreatment with 1 mg/mL KRG protected cells from CDDP ototoxicity. This protection was mainly due to a decline in apoptotic gene expression and an increase in antiapoptotic gene expression. In the in vivo part of the study, we found that both KRG doses had otoprotective effects. This protection was more prominent at the lower dose, especially on the spiral ganglion and the brainstem.

CONCLUSION: KRG was shown to be an otoprotective agent against CDDP-induced ototoxicity both in vivo and in vitro.

KEYWORDS: Cisplatin, ototoxicity, Korean Red Ginseng

INTRODUCTION

Cisplatin (CDDP) is one of the main agents in majority of chemotherapy protocols. Side effects such as ototoxicity, neurotoxicity, and nephrotoxicity are restricting its usage in both children and adult patients. Ototoxicity could lead to language and speech disabilities in young children^[1-2]. The mechanism of CDDP-induced ototoxicity is apoptosis, and outer hair cells, stria vascularis, and spiral ganglion neurons are mainly affected^[3-7].

Ginseng is a tonic that has been used in traditional far-east medicine for more than 2000 years. Korean Red Ginseng (KRG) has been extracted from the roots of Panax Ginseng. KRG has beneficial effects on learning and memory impairment. KRG has been found to be effective in various problems that cause hearing loss such as gentamycin ototoxicity, age-related hearing loss, or 3-nitropropionic acid-induced cochlear damage^[8-12]. CDDP-induced hearing loss has been studied in one in vitro and in one in vivo study^[8, 13]. The aim of this study was to evaluate the effects of different doses of KRG on CDDP ototoxicity both in vitro and in vivo. In the first part of the study, the effects of KRG on CDDP ototoxicity in the HEI-OC1 cell line were studied. In the second part of this study, the effect of KRG was evaluated in a rat model of CDDP ototoxicity.

MATERIALS and METHODS

Part I: In Vitro Study

The Local Ethics Committee for non-invasive studies at our University approved this study.

Presented in: This study was presented as an oral presentation at 1st Global Otologic Research Meeting, 13 November 2013, Antalya, Turkey.

Corresponding Address: Yüksel Olgun E-mail: yuksel.olgun@deu.edu.tr

Submitted: 22.12.2015

Revision received: 22.03.2016

Accepted: 28.03.2016

Available Online Date: 03.08.2016

©Copyright 2016 by The European Academy of Otology and Neurotology and The Politzer Society - Available online at www.advancedotology.org




Figure 1. Cells were exposed to 10, 20, 40, 100, 200, and 400 μ M doses of cisplatin. Fifty percent of cell growth in HEI-OC1 cells was inhibited at 20 μ M cisplatin dose after 24 h incubation




Figure 2. Apoptosis was decreased with a combination of KRG-CDDP. Asterisk indicates significance relative to CDDP (Mann-Whitney U, $p < 0.05$). Values represent the mean \pm SEM of 3 observations.

Cell Culture

The House Ear Institute-Organ of Corti 1 (HEI-OC1) cell line, an immortalized cell line derived from cochlear cultures of Immortomouse, was obtained from F. Kalinec from the House Ear Institute (Los Angeles, CA, USA). Ginseng extract used in this study was kindly provided from the Korean Red Ginseng Corporation (Taejon, Korea) with the support of Prof. Chong Sun Kim from Seoul National University. Cisplatin vials (Cisplatin-Ebewe® 50 mg/100 mL, Liba; İstanbul, Turkey) and Thiazolyl Blue Tetrazolium Blue MTT (Sigma) were used for the study. All chemicals and solutions were freshly prepared before each experiment. HEI-OC1 cells were exposed to CDDP at 10, 20, 40, 100, 200, and 400 μ M doses for growth inhibition experiments.

Korean Red Ginseng extract was used in 0.1, 1, and 10 mg doses. For KRG and CDDP combination experiments, the cells were exposed to KRG for 60 min and then incubated with CDDP for 24 h.

Cell Survival Analysis

Analysis was performed using MTT as published before. All assays were replicated 6 times [14, 15].

Apoptosis Analysis with TUNEL

Apoptosis was analyzed with the TUNEL (terminal gated deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling) assay. The Gen Script TUNEL Apoptosis Detection Kit (Cat. No. L00299, for Adherent cells, FITC-labeled POD) was used according to the manufacturer's instructions [14, 15]. Cells from all groups were smeared on polylysine-coated slides, dried, and fixed with methanol for 5 min. After blocking and proteinase K application, slides were incubated with TdT at 37 °C for 60 min. After application of the secondary antibody, the cells that had TdT attached to double strand DNA breaks were colored with Diaminobenzidine. 5000 cells were counted and the apoptosis ratio was scored as %.




Figure 3. After 60 min pretreatment with 1 mg/mL KRG, cells were protected from 20 μ M CDDP-induced toxicity. KRG showed a significant protective effect. Values represent the mean \pm SEM of 3 observations.




Figure 4. a-d. Ultrastructure of HEI-OC1 Cells. Control (a), KRG (b), CDDP+KRG (c), and CDDP (d). Hair cells show normal morphology (Red arrows); microvilli-like cytoplasmic prolongations, (a, b) (*): nucleus. Hair cell with normal morphology (*) with protected microvilli-like prolongations (red arrow): Apoptotic hair cell (*) and an abundance of cytoplasmic debris in the pericellular space (green arrow) (c).

Ultrastructural Findings of HEI-OC1 Cells by Transmission Electron Microscopy

Four groups of HEI-OC1 cells were analyzed with transmission electron microscopy. Groups were HEI-OC1 cells without any treatment, CDDP (20 μ M) treated HEI-OC1 cells, KRG (1 mg) treated HEI-OC1 cells, and HEI-OC1 cells treated with a combination of CDDP (20 μ M) and KRG (1 mg). The cells were collected by a cell scraper from the cell culture after incubation with the agents. Cells were fixed with glutaraldehyde and prepared by blocking in resin for routine electron microscopy experiments.

Analysis of Apoptosis-Related Gene Expressions

Ribonucleic acid isolation was performed using an RNA extraction kit. Apoptosis-related gene expression analysis was done with the standard 84 array genes of Mouse apoptosis (SABiosciences; Valencia, USA) by real-time PCR as previously published [16].




Figure 5. The list and heat map presentation of apoptotic gene expressions induced by KRG, CDDP, and the KRG-CDDP combination versus those of the control group. H lines were the array controls (housekeeping genes in H1–5, 1 genomic DNA control in H6, 3 reverse transcriptase controls in H7–9; 3 positive PCR controls in H10–12 lines). The H1–12 lines are not presented in the table. Green color indicated a lower expression of genes, and red color indicated a higher expression of genes.

Statistical Analysis

Statistical analysis was performed using the SPSS 15.0 software program (Statistical Package for Social Sciences; SPSS Inc.; Chicago, IL, USA). Results were evaluated as mean±SEM. A Mann–Whitney U test was used for comparison of continuous variables. In order to obtain statistically correct data, all experiments were repeated a minimum of 3 times. $P < 0.05$ value was accepted as statistically significant.

RESULTS

Cell Viability and Apoptotic Cell Death

CDDP decreased the viability of HEI-OC1 cells in a dose- and time-dependent manner. Cells were exposed to 10, 20, 40, 100, 200, and 400 μ M doses of CDDP. Fifty percent of cell growth was inhibited at 20 μ M cisplatin after 24 h incubation in HEI-OC1 cells (Figure 1). This dose was chosen for the rest of the experiment and was used for 24 h. Cells were pretreated with the KRG extract with 0.1 mg/mL, 1 mg/mL, and 10 mg/mL concentrations for 60 min. Protection was dose dependent, and the maximal effect was observed after 60 min of pre-

treatment with 1 mg/mL KRG. A 1 mg/mL dose of KRG was used for the rest of the experiments. This dose was shown to protect against CDDP ($p < 0.05$) (Figure 2, 3).

Transmission Electron Microscopic Findings

In group I (Control) and group II (KRG) microvilli-like cytoplasmic cellular prolongations were seen as previously observed in cultured epithelial and neuroepithelial cells. These prolongations were prominent in the longitudinal, horizontal, and oblique sections in pericellular spaces. Apoptotic, necrotic, and apoptotic cell morphologies were scarcely detected. In the CDDP group, large amounts of nuclear fragmentation, as well as apoptotic and necrotic cell nuclei, were detected. Plenty of cellular debris was found in the pericellular space. Some of the cells were apoptotic, others had either necrotic or apoptotic character. The rest of the cells were fusiform and oval shaped as usually seen in cultured cell mediums. Mitochondrial swellings were obvious. In the CDDP and KRG combination group, there were a few necrotic cells but apoptotic and apoptotic cells were very rare. The rest of the cells were heterochromatic and had normal nuclear morphology. Mitochondrial morphology was also normal (Figure 4).




Figure 6. a-e. Cresyl violet staining of the brainstem. Arrows shows pyknotic cells. Control group (a), KRG group (b), CDDP group (c), CDDP+KRG 500 mg group (d), CDDP+KRG 150 mg group (e).




Figure 7. a-e. TUNEL staining of the brainstem. Arrows showing TUNEL-positive cells. Control group (a), KRG group (b), CDDP group (c), CDDP+KRG 500 mg group (d), CDDP+KRG 150 mg group (e).

Apoptosis-Related Gene Expression Analysis

CDDP-, KRG-, and KRG-CDDP-induced apoptotic gene expressions were analyzed with the standard 84 array genes for mouse apoptosis (SA, Biosciences; Valencia, USA) (Figure 5). The results of gene analysis showed that CDDP could cause an increase in apoptotic genes such as caspase-8 and genes from the TNF family (Cd40, Cd70). In the CDDP+KRG group, apoptotic gene expression, particularly caspase-8 expression, was reduced. In this group also expression of antiapoptotic genes such as genes from the bcl2 family (bcl2, bcl211, bcl212, and Akt1) were increased.

In the vitro part of this study, KRG was shown to be partially protective against CDDP-related ototoxicity. The molecular mechanism of this protection was mainly due to a decline in apoptotic gene expression and an increase on antiapoptotic gene expression.

Part II: *In Vivo* Study

Materials and Methods

The protocol for this study was approved by the local ethics committee of the University for animal care and use. This study was conducted on 30 adult male Wistar albino rats weighing 200–300 g. Animals with any external or middle ear diseases were excluded from the study.




Figure 8. a-e. Brainstem Caspase-3 staining: Arrows showing Caspase-3-positive cells. Control group (a), KRG group (b), CDDP group (c), CDDP+KRG 500 mg group (d), CDDP+KRG 150 mg group (e).




Figure 9. a-e. The ultrastructure of hair cells. A1: Control group, A2: KRG group, A3: CDDP group, A4: CDDP+KRG 500 mg group, A5: CDDP+KRG 150 mg group. In the control (a), hair cells with normal ultrastructural properties were seen and cilia (red arrows) were preserved. In the KRG group (b), hair cells with regular nucleus (N) and cilia (red arrows) were seen. In the CDDP group (c), loss of cilia (red arrow) and intracellular degenerative spaces (*) were observed. In the CDDP+KRG 500 mg group (d), cilia were well preserved. In the CDDP+KRG 150 mg group (e), cilia (red arrows) were well preserved (Red arrow: cilia; *: intracellular degenerative areas).

Cisplatin vials (Cisplatin-Ebewe® 50 mg/100 mL, Liba; İstanbul, Turkey) were used for the experiment. Korean Red Ginseng Powder was used for in vivo study. This material was also provided by the Korean Red Ginseng Corporation (Taejon, Korea) with kind support from Professor Chong Sun Kim from Seoul National University. For groups II, IV, and V, 500 mg, 500 mg, and 150 mg of KRG powder was freshly diluted with 0.75 mL saline solution for oral administration.

Experimental Design

Study groups were divided as follows:

Group I (n=5): Saline control

Group II (n=5): 500 mg/kg/day KRG

Group III (n=6): 16 mg/kg CDDP

Group IV (n=7): 500 mg/kg/day KRG+CDDP

Group V (n=7): 150 mg/kg/day KRG+CDDP




Figure 10. a-e. The ultrastructure of spiral ganglion cells. In the control (a) and KRG group (b), spiral ganglion neurons nucleus (star) and satellite cells (arrowhead) were preserved. In the CDDP group (c), degenerative ganglion cells with irregular cell membranes and intracellular degenerative areas (yellow arrows) were evident. In the CDDP+KRG 500 mg (d) group, satellite cells (arrowhead) were preserved, CDDP+but there were a few intracellular degenerative areas in the cells (yellow arrow). In the CDDP+KRG 150 mg group (e), cell morphology was close to the control group with preserved satellite cells (arrowhead).

Star: nucleus; Arrowhead: satellite cell; Yellow arrow: intracellular degenerative areas.

Groups I and III rats received oral saline (0.75 mL/day) for 10 days. Groups II, IV (500 mg/kg KRG diluted into 0.75 mL saline/day) and V rats (150 mg/kg KRG diluted into 0.75 mL saline/day) were orally given KRG for 10 days. At the 11th day, a single dose of 16 mg/kg CDDP was infused intraperitoneally in groups III, IV, and V. The same volume of saline solution was infused intraperitoneally to groups I and II.

Auditory Assessments

Ketamin hydrochloride (Pfizer; İstanbul, Turkey) (60 mg/kg) and xylazine hydrochloride (Sigma-Aldrich; Lyon, France) (5 mg/kg) was used for anesthesia prior to each auditory investigation. A baseline distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) recording were obtained at the beginning of the study. At 14th day of the study, final audiological investigations were performed.

All recordings were obtained using the same procedures as previously published [16].

Histopathological Examinations

Following the final audiological investigations, the rats were sacrificed under ether anesthesia and the brainstem and temporal bullae were collected. Brainstem samples were investigated under light microscopy by staining with cresyl violet and also evaluated with TUNEL and caspase 3 immunohistochemistry methods as previously published [16].

Inner ear tissue samples were evaluated with transmission electron microscopy according to the previously published method [16].

Statistical Analysis

Statistical analyses were performed using the SPSS 15.0 software package (Statistical Package for Social Sciences; SPSS Inc.; Chicago, IL, USA). Results were given as mean±SEM. All obtained data were analyzed using one-way analysis of variance (ANOVA) and a post hoc Bonferroni test ($p < 0.05$ was accepted as statistically significant).

Table 1. Apoptosis ratio in the brainstem

Groups	TUNEL (%)	Caspase-3 (%)
Control	8.67±0.66 [#]	7.0±0.63 [#]
KRG	8.6±1.14 [#]	7.0±0.54 [#]
CDDP	30.1±4.75 [*]	27.1 ±1.92 [*]
CDDP+KRG 500 mg	25.4±1.51 [*]	23.2±0.96 [*]
CDDP+KRG 150 mg	19.8±1.92 ^{*#}	18.0±0.83 ^{*#}

KRG: Korean Red Ginseng; CDDP: cisplatin; TUNEL: Tdt-mediated dUTP Nick End Labeling

^{*}Statistically significant compared to the control group.

[#]Statistically significant compared to the cisplatin group.

Results

Audiological Findings

Baseline ABR and DPOAE values were not statistically different for all groups ($p > 0.05$). All test parameters of Group II animals were similar to those of the controls ($p > 0.05$). In CDDP group animals, click ABR thresholds were elevated and 8 kHz DPOAE thresholds were lower than in the controls ($p < 0.05$). In Group IV and V rats, ABR and DPOAE thresholds were not statistically different from the controls ($p > 0.05$).

Histological Examination

Cresyl Violet Staining

All sections were taken from the same area in the brainstem. The cochlear nuclei of the brainstem showed normal morphology in control and KRG only groups. In the CDDP group, the majority of the neurons were shrunken and pyknotic. In both CDDP and KRG combination groups, the number of shrunken neurons were diminished; however, this decrease was more prominent in the 150 mg/kg KRG+CDDP group (Figure 6).

TUNEL Assay

Apoptosis was evident in the CDDP group; TUNEL-positive cells were statistically higher than in the controls ($p < 0.05$). Apoptotic cell death diminished in group IV, but this decrease was not significant ($p > 0.05$). In group V (150 mg/kg KRG+CDDP), TUNEL-positive cells were significantly decreased in comparison to the CDDP group ($p < 0.05$) (Figure 7, Table 1).

Caspase-3 Immunohistochemistry

Immunohistochemical analysis of the rat brainstem revealed caspase-3 reactivity was significantly increased in the CDDP group in comparison with the control and KRG only groups ($p < 0.05$). This reactivity was less obvious in groups IV and V; however, it was statistically significant only for group V ($p < 0.05$) (Figure 8, Table 1).

Electron Microscopy Findings for the Organ of Corti

In control and KRG only groups, cell membranes, nuclei, and mitochondria from hair cells showed normal properties. In the CDDP group, the ultrastructure of hair cells was disturbed; cellular membranes were irregular, stereocilia were missing, and some intracellular degenerative spaces were seen. In groups IV and V, cellular damage was less evident. Cell membranes and cilia of hair cells were close to normal with very few intracellular degenerative areas (Figure 9).

Electron Microscopy Findings for the Spiral Ganglion

The control and KRG only groups showed normal spiral ganglion neuron properties. In the CDDP group, some irregularities at cell nucleus

and at the cellular membranes were seen. There were cytoplasmic degenerative spaces and losses of satellite cells. In groups IV and V, the ultrastructure of cells were near normal, but in the KRG 500 mg/kg+CDDP group, degenerative areas were still seen. The morphology of the 150 mg/kg KRG+CDDP group's spiral ganglion cells and satellite cells were closer to normal (Figure 10).

The second part of the study showed that KRG had protective effects against cisplatin cochlear damage. This effect was more prominent with lower doses of KRG and at the neuron level.

DISCUSSION

Ototoxicity is an important side effect resulting from anticancer treatment. Hearing loss can cause considerable problems in the social life of both children and adults. Specifically, in small children, it can impair speech and language acquisition. In the elderly population, hearing loss may be associated with social isolation^[17]. CDDP leads to the activation of intrinsic and extrinsic apoptotic pathways. While the intrinsic pathway activates with the release of cytochrome-c from the mitochondria, the extrinsic pathway activates by ligand binding to death receptors such as Fas and tumor necrosis factor receptor-1 (TNFR1)^[3-7, 9, 10]. Some candidate agents such as sodium thiosulfate, D- or L-methionine, lipoic acid, N-acetyl cysteine, acetyl L-carnitine, alpha tocopherol, and resveratrol were studied both in vitro and in vivo to analyze their protective effects against CDDP-induced ototoxicity^[7, 16, 18-21]. However, none of them are currently approved for usage against CDDP-induced ototoxicity.

Ginseng is a herbal medicine taken orally. It is considered a general tonic and is believed to enhance body homeostasis. It is prescribed in oriental medicine predominately for anti-aging, anti-stress effects, and to increase physical health. Its bioavailability is low. Gut microbial flora is responsible for the production of different metabolites such as ginsenosides, polysaccharides, peptides, and gintonins^[22, 23]. However, because of poor membrane permeability and low solubility, absorption of these products is limited. More than 100 ginsenosides have been isolated from panax ginseng (KRG).

These ginsenosides, chemically, are steroids. Different ginsenosides with other ginseng saponins have different effects. Some of these effects may differ in different doses. Ginsenosides have been shown to decrease excitability of neuronal cells by stimulating GABA and glycine receptors^[24]. Neuroprotective and anxiolytic effects of ginseng are attributed to this action. Cardioprotective and antihypertensive effects of KRG are mostly linked to the relaxation of blood vessels in smooth muscle, inhibition of endothelin production, as well inhibition of platelet aggregation^[24].

Some saponins are responsible for anti-inflammatory and immune stimulating properties of KRG by inhibiting leukotrienes, histamine release, and cytokine production and enhancing phagocytosis in B and T cells. However, KRG is consumed after traditional extraction processes and, like many other natural products, cultivation and processing conditions may alter the compositions of ingredients^[24]. Because some of the ginsenosides may cause a change in the pharmacodynamics of others, it may not be easy to distinguish which one is responsible for a given effect when they are all taken orally.

Age-related hearing loss, noise-induced hearing loss, and ototoxicity has been shown to occur as a result of an apoptotic process^[3-7]. KRG extracts, or its specific saponins, were shown to have antiapoptotic and antioxidant properties in various tissues both in vitro and in vivo^[8]. Recently, it was shown that KRG has otoprotective properties against gentamicin^[9, 10], 3-nitropropionic acid^[12], and CDDP-induced ototoxicity^[8, 13]. These studies revealed that KRG mainly works by inhibition of some proapoptotic genes such as caspase-1, caspase-3, and the TNF family of genes and by enhancement of antiapoptotic gene expression such as bcl-2^[8-13]. On the other hand, KRG has antiapoptotic effects on neuronal tissues^[18]. It was shown that this effect mainly works by up regulation of the p13K/Akt signaling pathway, which is a cell survival pathway. Activation of this pathway inhibits apoptosis by decreasing p53 and caspase-3 expression while also increasing expression of genes in the bcl2 family^[8, 11, 18]. KRG has also been shown to be an otoprotective agent following cochlear injury associated with noise-induced hearing loss^[25]. Moreover, in a clinical study conducted by Kim^[26], the beneficial effects of orally administered KRG on chronic tinnitus symptoms was demonstrated.

This study was conducted in two stages. In the first stage, KRG was tested on HEI-OC1 cells against CDDP ototoxicity. Although in some studies, specific ginsenosides have been used, we preferred to use ginseng extract as it is easily orally taken in daily life. A combination of KRG and CDDP blocked extrinsic pathways by decreasing caspase-8 gene expression. Also it inhibited intrinsic pathways by increasing expressions of bcl-2 family gene. Besides, an increase of Akt1 gene expression has been shown and this expression was thought to have caused activation of another signaling pathway that leads to cell survival by blocking apoptosis.

These findings are in accordance with previous studies that reveal KRG prevents apoptosis by inhibiting extrinsic and intrinsic pathways, as well by activating cell survival pathways^[3-8, 11, 18].

As we revealed in the first part of this study, the effect of KRG is time and dose dependent. In the second part of this study, we preferred using two different doses of KRG. Otoprotective effects of KRG were studied in rats in different conditions such as age-related hearing loss and vestibular dysfunction^[11], acute 3-nitropropionic-induced cochlear damage, gentamicin-induced hearing loss and balance dysfunction, and CDDP-induced ototoxicity^[9, 10, 12]. Audiological evaluation, as well scanning electron microscopy and confocal microscopy findings, revealed that KRG has a protective effect against gentamicin and 3-nitropropionic acid-induced ototoxicity^[9, 10, 12].

Recently, Tian et al.^[11] used KRG in a two-stage study. In the in vivo part, they found that KRG showed protective effects against CDDP-induced ototoxicity in rats, as shown by ABR results. They also worked on organ of corti explant cultures and found that pretreatment with KRG prevents hair cell impairment^[11].

We used DPOAE and ABR to evaluate hearing levels and we found that both 150 mg and 500 mg doses of KRG had otoprotective effects against CDDP-induced ototoxicity.

Sections through the cochlear nuclei of brainstem cells proved that 150 mg/kg/day KRG was more effective against CDDP-induced ototoxicity.

Although with 500 mg/kg/day KRG, the apoptotic cell ratio diminished, this decrement was not significant in comparison to the CDDP group.

Transmission electron microscopy findings showed that treatment with both 150 mg and 500 mg KRG offered protection at the cochlea level. In both treatment groups, spiral ganglion neurons were protected; and this protection was more prominent in the 150 mg/kg/day KRG group. These observations suggest that, although both doses of KRG show otoprotective properties, in lower doses (150 mg/kg) neural tissues such as the spiral ganglion and the brainstem are better protected.

Recently, it was shown that antiapoptotic agents can act differently depending on the used dose. In a recent study, lower doses of KRG was found to be effective in preventing age-related hearing and vestibular dysfunction. But in the same study, it was revealed that a higher dose (500 mg/kg) of KRG aggravated age-related hearing loss and balance dysfunction^[11]. Similarly, it was found that while high doses of oral resveratrol increased CDDP-induced ototoxicity and apoptosis, in a lower dose of oral resveratrol, some histopathological improvement was observed. In light of our findings, and the literature, we believe that different doses should be tried in any study concerning this kind of antiapoptotic agents before these studies can be translated to clinical practice.

In conclusion, KRG has a protective effect on HEI-OC1 cells in a dose- and time-dependent manner. This effect mainly worked on increasing antiapoptotic gene expression and decreasing apoptotic gene expression. Moreover, KRG was shown to be effective against CDDP-induced ototoxicity in rats. This effect is more prominent in low doses, particularly on neuronal tissues such as spiral ganglion neurons and the brainstem. Our study can be considered as a frontier for translational studies, and KRG in low doses may be a good nutrient to use in clinical trials against CDDP ototoxicity.

Ethics Committee Approval: Ethics committee approval was received for this study from the Local Ethics Committee of Dokuz Eylül University School of Medicine.

Informed Consent: N/A.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - Y.O.; Design - Y.O., S.A., Z.S.; Supervision - E.A.G.; Materials - Y.O., Z.A., S.A., G.K., O.Y.; Data Collection and/or Processing - Y.O., G.K., E.K., M.K., A.B., D.Ç.K., A.O., P.E.; Analysis and/or Interpretation - C.Ö., H.E., M.K.; Literature Review - Y.O., A.O., D.Ç.K.; Critical Review - E.A.G., B.Ş.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

REFERENCES

- Berg AL, Spitzer JB, Garvin JH Jr. Ototoxic impact of cisplatin in pediatric oncology patients. *Laryngoscope* 1999; 109: 1806-14. [\[CrossRef\]](#)
- Qaddoumi I, Bass JK, Billups CA, Wozniak AW, Merchant TE, Haik BG, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. *J Clin Oncol* 2012; 30: 1034-41. [\[CrossRef\]](#)
- Rybak LP. Mechanisms of cisplatin ototoxicity and progress in otoprotection. *Curr Opin in Otolaryngol Head Neck Surg* 2007; 15: 364-9. [\[CrossRef\]](#)
- Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. *Trends Pharmacol Sci* 2013; 1059: 1-12. [\[CrossRef\]](#)
- Ali I, Wani WA, Saleem K, Haque A. platinum compounds: A hope for future cancer chemotherapy. *Anticancer Agents Med Chem* 2013; 13: 296-306. [\[CrossRef\]](#)
- Rybak LP, Whitworth CA. Ototoxicity therapeutic opportunities. *Drug Discovery Today* 2005; 10: 1313-21. [\[CrossRef\]](#)
- Olgun Y. Cisplatin Ototoxicity: Where we are? *J Int Adv Otol* 2013; 9: 403-16.
- Im GJ, Chang JW, Choi J, Chae SW, Ko EJ, Jung HH. Protective effect of Korean red ginseng extract on cisplatin ototoxicity in HEI-OC1 auditory cells. *Phytother Res* 2010; 24: 614-21.
- Choung YH, Kim SW, Tian C, Min JY, Lee HK, Park SN, et al. Korean red ginseng prevents gentamycin-induced hearing loss in rats. *Laryngoscope* 2011; 121: 1294-302. [\[CrossRef\]](#)
- Tian CJ, Kim SW, Kim YJ, Lim HJ, Park R, So HS, et al. Red ginseng protects against gentamycin-induced balance dysfunction and hearing loss in rats through antiapoptotic functions of ginsenoside Rb1. *Food Chem-Toxicol* 2013; 60: 369-76. [\[CrossRef\]](#)
- Tian C, Kim YJ, Lim HJ, Kim YS, Park HY, Choung YH. Red ginseng delays age-related hearing and vestibular dysfunction in C57BL/6 mice. *Exp Gerontol* 2014; 57: 224-32. [\[CrossRef\]](#)
- Tian C, Kim YH, Kim YC, Park KT, Kim SW, Kim YJ et al. Korean red ginseng ameliorates acute 3-nitropropionic acid-induced cochlear damage in mice. *Neurotoxicology* 2013; 34: 42-50. [\[CrossRef\]](#)
- Kim SJ, Kwak HJ, Kim DS, Choi HM, Sim JE, Kim SH, et al. Protective mechanisms of Korean red ginseng in cisplatin-induced ototoxicity through attenuation of nuclear factor- κ B and caspase-1 activation. *Molecular Medicine Reports* 2015; 12: 315-22.
- Olgun Y, Altun Z, Aktas S, Erçetin P, Kırkım G, Kiray M, et al. Molecular mechanism of protective effect of resveratrol against cisplatin-induced ototoxicity. *Int Adv Otol* 2013; 9: 145-52.
- Altun Z, Olgun Y, Erçetin P, Aktas S, Kırkım G, Şerbetçioğlu B, et al. Protective effect of acetyl-L carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines. *Cell Prolif* 2014; 47: 780. [\[CrossRef\]](#)
- Olgun Y, Kırkım G, Kolatan E, Kiray M, Bağrıyanık A, Olgun A. Friend or Foe? Oral resveratrol on cisplatin ototoxicity. *Laryngoscope* 2014; 124: 760-6. [\[CrossRef\]](#)
- Mick P, Pichora-Fuller MK. Is hearing loss associated with poorer health in older adults who might benefit from hearing screening? *Ear Hear* 2016; 37: e194-201. [\[CrossRef\]](#)
- Nguyen CT, Luong TT, Kim GL, Pyo S, Rhee DK. Korean red ginseng inhibits apoptosis in neuroblastoma cells via estrogen receptor β -mediated phosphatidylinositol-3 kinase/Akt signalling. *J of Ginseng Research* 2015; 39: 69-75. [\[CrossRef\]](#)
- Nakayama A, Alladin KP, Igboke O, White JD. Systematic Review: Generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy. *Cancer Inves* 2011; 29: 655-67. [\[CrossRef\]](#)
- Mujherjea D, Ghosh S, Bhatta P, Sheth S, Tupal S, Borse V, et al. Early investigational drugs for hearing loss. *Expert Opin Investig Drugs* 2014; 24: 1-17.
- Lynch ED, Kil J. Compounds for the prevention and treatment of noise-induced hearing loss. *Drug Discovery Today* 2006; 10: 1291-7. [\[CrossRef\]](#)
- Qi LW, Wang CZ, Du GJ, Zhang ZY, Calway T, Yuan CS. Metabolism of ginseng and its interactions with drugs. *Curr Drug Metab* 2011; 12: 818-22. [\[CrossRef\]](#)
- Im DS, Nah SY. Yin and Yang of ginseng pharmacology: ginsenosides vs gintonin. *Acta Pharmacol Sin* 2013; 34: 1367-73. [\[CrossRef\]](#)
- Chen CF, Chiou WF, Zhang JT. Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium. *Acta Pharmacol Sin* 2008; 29: 1103-8. [\[CrossRef\]](#)
- Hong BN, Kim SY, Yi TH, Kang TH. Post-exposure treatment with ginsenoside compound K ameliorates auditory functional injury associated with noise-induced hearing loss in mice. *Neurosci Lett* 2011; 487: 217-22. [\[CrossRef\]](#)
- Kim TS, Lee HS, Chung JW. The Effect of Korean red ginseng on symptoms and quality of life in chronic tinnitus: A randomized, open-label pilot study. *J Audiol Otol* 2015; 19: 85-90. [\[CrossRef\]](#)